跳至主要内容
临床试验/NCT00307944
NCT00307944已完成4 期

Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing

University of Cincinnati2 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2004年8月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
68
试验地点
2
主要终点
Difference between treatment groups with regard to change in sleepiness score (ESS)

研究概览

简要总结

The purpose of this study is to determine if using Pantoprazole decreases your daytime sleepiness and improves your reaction time when compared to using a placebo (sugar pill).

详细描述

Half of the patients enrolled in the study will begin the study taking Pantoprazole. The other half will begin the study taking a placebo (sugar pill). There is an equal chance of being placed in either group.

After two weeks, the patients will stop taking their first batch of medication to allow it to completely leave their bodies. Then the patients will begin taking the other medication so that by the end of the study, each patient will have been treated with pantoprazole for two weeks and placebo for two weeks.

At the end of each two weeks, patients will be asked to complete questionnaires regarding their daytime sleepiness and reflux symptoms. Patients will also complete reaction time testing as a measure of daytime sleepiness.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 or older
  • Daytime sleepiness (ESS >= 8)
  • Mild to moderate OSD (AHI<=30)
  • Symptoms of GERD
  • Symptoms of acid reflux

排除标准

  • Pregnant or trying to become pregnant
  • Depression or unstable psychiatric disorder
  • Allergy to Pantoprazole
  • Taking a proton pump inhibitor within the last month
  • Taking a histamine-2 receptor blocker within the last month
  • Automobile or industrial accident due to daytime sleepiness
  • Currently taking ketoconazole, itraconazole, ampicillin or iron salts
  • Hypersecretory acid disorder (Zollinger-Ellison Syndrome)
  • Active peptic ulcer disease
  • Severe concomitant disease of another major body system
  • Malignancy in the past 5 years
  • Current abuse of alcohol, medication or drugs
  • Sedative medications
  • Additional treatment for obstructive sleep apnea (i.e. CPAP or surgery)

结局指标

主要结局

Difference between treatment groups with regard to change in sleepiness score (ESS)

次要结局

  • Difference between treatment groups with regard to change in reaction time testing.
  • Difference between treatment groups with regard to change in total reflux symptom scores.
  • Difference between treatment groups with regard to change in sleep related QOL (FOSQ).

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验